Comparison · NCT01244191-deaths
Tivantinib and Erlotinib vs Placebo and Erlotinib: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Tivantinib and Erlotinib vs Placebo and Erlotinib: deaths from any cause. Trial comparisons, record NCT01244191-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01244191-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.148 | 0.12 | 0.181 | wilson | |
| Risk in group 2 | 0.126 | 0.0999 | 0.157 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0224 | -0.0197 | 0.0644 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.18 | 0.867 | 1.6 | log | |
| Odds ratio, group 1 over group 2 | 1.21 | 0.847 | 1.72 | log | |
| Number needed to harm, for one more death from any cause on Tivantinib and Erlotinib than on Placebo and Erlotinib | 44.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Tivantinib and Erlotinib | Participants who were randomized to receive Tivantinib 720 mg daily (360 mg twice a day) in combination with 150 mg of erlotinib, given once a day. | 77 | 520 | EG000 |
| Group 2 | Placebo and Erlotinib | Participants who were randomized to receive Tivantinib placebo given twice a day in combination with 150 mg of erlotinib, given once a day. | 65 | 517 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Adverse events were collected from baseline up to 30 days after last dose, up to approximately 1 year 11 months postdose.
Source ClinicalTrials.gov
Trial
- Title
- Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
- NCT number
- NCT01244191
- Phases
- PHASE3
- Conditions
- Non Squamous, Non-small-cell Lung Cancer
- Interventions
- Tivantinib, Placebo, Erlotinib
- Lead sponsor
- Daiichi Sankyo
- Results first posted
- 2020-10-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01244191?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01244191-deaths